Search clinical trials for: 68-Ga-DOTANOC

Total 477 results

Mingkwan Wongyingsinn, MD

Completed

Local or Regional or General Anesthesia for Hernia Repair: a Randomized Controlled Trial

Inflammation | Hernia | Anesthetics Adverse Reaction

Thailand
Fudan University
Washington University School of Medicine

Unknown

Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery

Cancer of Pancreas

China
Konya City Hospital
Van Training and Research Hospital

Completed

Open and Laparoscopic Total Extraperitoneal Repair Under Spinal Anesthesia Versus General Anesthesia

Pain, Postoperative | Postoperative Complications | Inguinal Hernia

Turkey
Medical University of Lublin
University of Rzeszow

Completed

Postoperative Analgesia After Minithoracotomy

Postoperative Pain | Mitral Valve Disease

Poland
McNeil AB

Completed

Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum

Tobacco Dependence

Sweden
Medical University of Lublin
Division of Cardiovascular Surgery, St. Jadwiga Provincial Clinical Hospital...

Completed

ESP vs ESP With PECS

Postoperative Pain | Mitral Valve Disease

Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Andrei Iagaru
General Electric

Completed

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Fatigue | Weight Loss | Fever | Splenomegaly | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1... and other conditions

United States
Fred Lublin
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Relapsing Remitting Multiple Sclerosis

United States, Canada
Morand Piert, MD

No longer available

Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer

Prostate Adenocarcinoma
Novartis Pharmaceuticals

Recruiting

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Breast Cancer

France, Germany, Spain, Portugal
Medical University of Lublin

Completed

ESP in Breast Surgery Due to Cancer

Breast Cancer | Anesthesia, Local | Pain, Acute

Poland
Centro Hospitalar do Porto
Universidade do Porto; Center for Health Technology and Services Research

Terminated

Anesthesia And Post-operative Mortality After Proximal Femur Fractures

Hip Fractures

Portugal
Wakayama Medical University

Unknown

Study of NAC of GA Therapy for Patients With BRPC

Pancreatic Ductal Adenocarcinoma

Japan
M.D. Anderson Cancer Center

Terminated

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

Brain Tumors | Central Nervous System Tumors

United States
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; United States Department of Defense

Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Novartis Pharmaceuticals

Recruiting

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Glioblastoma

Spain, Switzerland, France, Portugal, United States
Joseph Tuscano
National Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.

Recruiting

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
University of Michigan
Centers for Disease Control and Prevention

Completed

Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza Transmission (M-FLU)

Influenza

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory... and other conditions

United States
Stanford University
National Cancer Institute (NCI)

Completed

68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

Prostate Carcinoma

United States
Elsan

Recruiting

Rotator Cuff Repair Under Isolated Loco-regional Anesthesia (AGORA)

Shoulder Cuff Surgical Repair

France
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, United Kingdom, Austria, Italy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Mayne Pharma International Pty Ltd

Completed

Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg

Neutropenia

Australia
University Hospital, Basel, Switzerland
Swiss Cancer League

Recruiting

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (PROMENADE)

Meningioma

Switzerland
ITM Solucin GmbH
ABX CRO; PSI CRO

Active, not recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

Neuroendocrine Tumors

Germany, France, United States, United Kingdom, Australia, Italy, Belgium, Switzerland, Czechia, Spain, Austria, Netherlands, Poland, South Africa
Emory University
National Cancer Institute (NCI); AstraZeneca

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Lymphoproliferative Disorder | Indolent Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Medical University of Lublin
Department of Anesthesiology and Intensive Care, F. Chopin Hospital in Rzeszów and other collaborators

Unknown

QLB After Nephrectomy

Pain, Postoperative | Chronic Postoperative Pain

Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Institut Pasteur
Institut Pasteur de Madagascar; Action Contre la Faim; Centre de Recherches Médicales... and other collaborators

Completed

Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old (MALINEA)

Moderate Acute Malnutrition

Central African Republic, Madagascar, Niger, Senegal
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers

Candidiasis | Dermatomycoses | Histoplasmosis | Superficial Mycoses

Korea, Republic of
University of Geneva, Switzerland
ITI Foundation

Recruiting

Two-unit Cantilever Implant Prostheses Made of Monolithic Zirconia or PFM (Cantilever)

Jaw, Edentulous, Partially | Missing Teeth

Switzerland
Mayne Pharma International Pty Ltd

Completed

Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis

Neutropenia

Australia
Italfarmaco

Completed

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

Duchenne and Becker Muscular Dystrophy | Polycytemia Vera

Canada
Beth Christian
Genentech, Inc.; Celgene

Active, not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
Novartis Pharmaceuticals

Recruiting

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Extensive Stage Small Cell Lung Cancer

Germany, Spain, United States, France, United Kingdom
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Zagazig University

Unknown

PECS Block With Bupivacaine Vs Bupivacaine and Dexmedetomidine in Modified Radical Mastectomy

Anesthesia

Egypt
Carina Mari Aparici

Withdrawn

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

Fever of Unknown Origin

United States
Thomas Jefferson University

Unknown

Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery

Colorectal Neoplasms | Inflammatory Bowel Diseases | Surgical Site Infection | Diverticulitis

United States
Assiut University

Completed

The Female Sexual Functions With Progestogen-only Contraception

Female Sexual Function

Egypt
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Stage Ib Lung Carcinoma | Stage IIA Lung Carcinoma | Stage IIIA Lung Carcinoma | Stage I Lung Cancer | Stage IA Lung Carcinoma AJCC V7

United States
University of California, San Francisco

Completed

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7

United States
Jean Yuh Tang
National Cancer Institute (NCI)

Completed

Topical Itraconazole in Treating Patients With Basal Cell Cancer

Skin Basal Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States

Search clinical trials for: 68-Ga-DOTANOC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations